XIIHIV/HCV共感染者での抗HIV療法

文献

  1. Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV coinfection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 16: 797-808.2106
  2. Bartlett SR, Wertheim JO, Bull RA, et al. A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies. J Viral Hepat. 24:404–11.2017
  3. Centers for Disease Control and Prevention. Sexual Transmission of Hepatitis C Virus Among HIV-Infected Men Who Have Sex with Men - New York City, 2005-2010. Morb Mortal Wkly Rep. 60:945-50.2011
  4. Foster AL, Gaisa MM, Hijdra RM, et al. Shedding of hepatitis C virus into the rectum of HIV-infected men who have sex with men. Clin Infect Dis. 64:284-88.2016.
  5. Nishijima T, Shimbo T, Komatsu H, et al. Incidence and risk factors for incident hepatitis C infection among men who have sex with men with HIV-1 infection in a large urban HIV clinic in Tokyo. J Acquir Immune Defic Syndr. 65(2):213-7.2014
  6. 小池和彦 HIV感染症に合併する各種疾病に関する研究.厚生労働科学研究費補助金エイズ対策研究事業 平成19年度総括・分担研究報告書.
  7. Koike K, Tsukada K, Yotsuyanagi H, et al. Prevalence of coinfection with human immunodeficiency virus and hepatitis C virus in Japan. Hepatol Res. 37:2-5. 2007
  8. Tatsunami S, Mimaya J, Shirahata A, et al. Current status of Japanese HIV-infected patients with coagulation disorders: coinfection with both HIV and HCV. Int J Hematol. 88:304-10. 2008
  9. Marco A, Esteban JI, Solé C, et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol. 59:45-51. 2013
  10. Lambers FA, Prins M, Thomas X, et al. Alarming incidence of HCV re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV MSM. AIDS. 25:F21-7. 2011
  11. Sarrazin C, Isakovv V, Svarovskaia ES, et al. Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies. Clin Infect Dis. 64:44-52. 2017
  12. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 13:34-41. 2006
  13. Danta M, Semmo N, Fabris P, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis. 197:1558-66. 2008
  14. Dionne-Odom J, Osborn MK, Radziewicz H, et al. Acute hepatitis C and HIV coinfection. Lancet Infect Dis. 9:775-83. 2009
  15. Kim AY, Schulze zur Wiesch J, Kuntzen T, et al. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med. 3:e492. 2006
  16. Kokordelis P, Krämer B, Körner C, et al. An effective interferon-gamma mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency virus-positive patients. Hepatology. 59:814-27. 2014
  17. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 48:418-31. 2008
  18. Stenkvist J, Nyström J, Falconer K, et al. Occasional spontaneous clearance of chronic hepatitis C virus in HIV-infected individuals. J Hepatol. 61:957-61. 2014
  19. Vispo E, Barreiro P, Plaza Z, et al. Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy. AIDS. 28:1473-8. 2014
  20. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 32:492-7. 2001
  21. HCV in HIV: Challenges and Opportunities. The PRN NOTEBOOK. 6:14-18. 2001. https://www.prn.org
  22. Fujinaga H, Tsutsumi T, Yotsuyanagi H, et al. Hepatocarcinogenesis in Hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species. Oncology. 81(suppl 1): 11-17. 2011
  23. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 43:365-72. 2006
  24. Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol. 44:1026-32. 2006
  25. Kim AY, Lauer GM, Ouchi K, et al. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood. 105:1170-8. 2005
  26. Pembroke T, Deschenes M, Lebouché B, et al. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV coinfected patients and is associated with liver fibrosis. J Hepatol. 67:801-8. 2017
  27. Woreta TA, Sutcliffe CG, Mehta SH, et al. Incidence and Risk Factors for Steatosis Progression in Adults Coinfected With HIV and Hepatitis C Virus. Gastroenterology. 140:809-17. 2011
  28. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 30:1054-8. 1999
  29. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 21:2209-16. 2007
  30. Martinez-Sierra C, Arizcorreta A, Díaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis.36:491-8. 2003
  31. Terrier B, Carrat F, Geri G, et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol. 55:756-61.2011
  32. Lin W, Weinberg EM, Tai AW, et al. HIV increases HCV replication in a TGF-β1-dependent manner. Gastroenterology. 134: 803–11. 2008
  33. Tuyama AC, Hong F, Saiman Y, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/ hepatitis C virus-induced liver fibrosis. Hepatology. 52: 612–22. 2010
  34. Seki E, Minicis S, Ӧsterreicher C, et al. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med.13: 1324–32. 2007
  35. Lidofsky A, Holmes JA, Feeney ER, et al. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. J Infect Dis. 218:1394-1403. 2018
  36. Bräu N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 47:527-37. 2007
  37. Salmon D, Bani-Sadr F, Loko MA, et al. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: Results from ANRS CO13 HEPAVIH. J Hepatol. 56(4):862-8. 2012
  38. Thein HH, Yi Q, Dore GJ, and Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A meta-analysis. AIDS. 22:1979-91. 2008
  39. Bräu N, Salvatore M, Ríos-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 44: 47–55. 2006
  40. Sherman KE, Andersen JW, Butt AA, et al. Sustained long-term antiviral maintenance therapy in HCV/HIV-Coinfected patients (SLAM-C). J Acquir Immune Defic Syndr. 15: 597–605. 2010
  41. Sterling RK, Wegelin JA, Smith PG, et al. Similar progression of fibrosis between HIV/HCV-infected and HCV- infected patients: analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol. 8: 1070–6. 2010
  42. Klein MB, Althoff KN, Jing Y, et al. Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis. 63: 1160-7. 2016
  43. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis.33:240-7.2001
  44. Yoo TW, Donfield S, Lail A, et al. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis. 191:4-10. 2005
  45. Daar ES, Lynn H, Donfield S, et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis. 183:589-95. 2001
  46. Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 36:363-7. 2003
  47. Cacoub P, Geffray L, Rosenthal E, et al. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis. 32:1207-14. 2001
  48. Haydon GH, Flegg PJ, Blair CS, et al. The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. Eur J Gastroenterol Hepatol.10:485-9. 1998
  49. Sulkowski MS, Moore RD, Mehta SH, et al. Hepatitis C and progression of HIV disease. JAMA. 288:199-206. 2002
  50. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 192:992-1002. 2005
  51. Kovari H, Rauch A, Kouyos R, et al. Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIVpositive persons in the Swiss HIV Cohort Study. Clin Infect Dis. 64:490-7. 2016
  52. Meijide H, Pertega S, Rodrıguez-Osorio I, et al. Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected. AIDS. 31:1099–107. 2017
  53. Alejos B, Hernando V, Iribarren J, et al. Overall and cause-specific excess mortality in HIV-positive persons compared with the general population: Role of HCV coinfection. Medicine (Baltimore). 95: e4727. 2016
  54. H Al-Mohri, T Murphy, Y Lu, et al. Evaluating Liver Fibrosis Progression and the Impact of Antiretroviral Therapy in HIV and Hepatitis C Coinfection Using a Noninvasive Marker. J Acquir Immune Defic Syndr. 44:463-9. 2007
  55. Berenguer J, Zamora FX, Aldamiz-Echevarria T, et al. Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 60:950-8.2015
  56. Macías J, Girón-González JA, González-Serrano M, et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut. 55:409-14. 2006
  57. Sánchez-Conde M, Montes-Ramírez ML, Miralles P, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat. 17:280–6. 2010
  58. Sánchez-Conde M, Miralles P, Bellón JM, et al. Use of transient elastography (FibroScan) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients. J Viral Hepat. 18:685–91. 2011
  59. Okanoue T, Itoh Y, Minami M, et al. Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts. Hepatol Res. 38:27-36. 2008
  60. Maida I, Soriano V, Barreiro P, et al. Liver fibrosis stage and HCV genotype distribution in HIV-HCV co-infected patients with persistently normal transaminases. AIDS Res Hum Retroviruses. 23:801-4. 2007
  61. Uberti-Foppa C, De Bona A, Galli L, et al. Liver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levels. J Acquir Immune Defic Syndr. 41:63–7. 2006
  62. Perez-Olmeda M, Garcia-Samaniego J, Soriano V, et al. Hepatitis C viremia in HIV/HCV-coinfected patients having immune restoration with highly active antiretroviral therapy. AIDS. 14:212. 2000
  63. Asmuth DM, Busch MP, Laycock ME, et al. Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection. Antiviral Res. 63:123-31. 2004
  64. Kottilil S, Jagannatha S, Lu A, et al. Changes in hepatitis C viral response after initiation of highly active antiretroviral therapy and control of HIV viremia in chronically co-infected individuals. HIV Clin Trials. 5:25-32. 2004
  65. Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS.16:1915-23. 2002
  66. Benhamou Y, DeMartinio V, Bochet M, et al. factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus co-infected patients: impact of protease inhibitor therapy. Hepatology. 34:283-7. 2001
  67. Kramer JR, Giordano TP, Souchek J, et al. The effect of HIV co-infection on the risk of cirrhosis and hepatocellular carcinoma. In U.S. veterans with hepatitis C. Am J Gastroenterol. 100:56-63. 2005
  68. Bräu N, Salvatore M, Ríos-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 44:47-55. 2006
  69. Qurishi N, Kleuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 362:1708-13. 2003
  70. Ragni MV, Nalesnik MA, Schillo R, et al. Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV coinfection. Haemophilia. 15:552-8. 2009
  71. Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 36: 363-7. 2003
  72. Mehta SH, Thomas DL, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology.41: 123-31. 2005
  73. Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 283:74-80. 2000
  74. Montaner JS, Hogg R, Raboud J, et al. Antiretroviral treatment in 1998. Lancet. 352:1919-22. 1998
  75. Martinez E, Gatell J. Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet. 352:821-2. 1998
  76. Brunet L, Moodie EE, Young J, et al. Progression of liver fibrosis and modern combination antiretroviral therapy regimens in HIV-hepatitis C-coinfected persons. Clin Infect Dis. 62: 242-9. 2016
  77. Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C co-infection. Clin Infect Dis. 38(suppl 2): S104-S108. 2004
  78. Atranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 40: 588-93. 2005
  79. Avidan NU, Goldstein D, Rozenberg L, et al. Hepatitis C Viral Kinetics During Treatment With Peg IFN-alpha-2b in HIV/HCV Coinfected Patients as a Function of Baseline CD4+ T-Cell Counts. J Acquir Immune Defic Syndr. 52: 452-8. 2009
  80. Rozera G, FabbriG, Lorenzini P, et al. Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals. Plos one.12(10):e0187095. 2017
  81. Deterding K, Grüner N, Buggisch P, et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis. 13:497-506. 2013
  82. Boesecke C, Rockstroh J. Acute hepatitis C in patients with HIV. Semin Liver Dis. 32:130-7. 2012
  83. Boesecke C, van Assen S, Stellbrink HJ, et al. Peginterferon-alfa mono-therapy in the treatment of acute hepatitis C in HIVinfection. J Viral Hepat. 21:780-5. 2014
  84. Ishikane M, Watanabe K, Tsukada K, et al. Acute Hepatitis C in HIV-1 Infected Japanese Cohort: Single Center Retrospective Cohort Study. PLoS One. 9:e100517. 2014
  85. Sacchi A, Agrati C, D'Offizi G, et al. The basal activation state of DC subsets correlates with anti-HCV treatment outcome in HCV/HIV co-infected patients. Clin Immunol. 138(2): 178-86. 2011
  86. Vargas A, Berenguer J, Ryan P, et al. Plasma interferon-gamma-inducible protein-10 can predict virologic response to hepatitis C virus therapy in HIV/HCV-coinfected patients with HCV genotype 1. J Acquir Immune Defic Syndr. 54:219-20. 2010
  87. Pineda JA, Caruz A, Rivero A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 51:788-95. 2010
  88. Aparicio E, Parera M, Franco S, et al. IL28B SNP rs8099917 is strongly associated with pegylated interferon-a and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One. 5:e13771. 2010
  89. Neukam K, Camacho A, Caruz A, et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol. 56:788-94. 2012
  90. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 364:2405-16. 2011
  91. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 364:2417-28. 2011
  92. Naggie S, Sulkowski MS. Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals. Gastroenterology.142:1324-34. 2012
  93. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 159:86-96.2013
  94. Cotte L, Braun J, Lascoux-Combe C, et al. Telaprevir for HIV/Hepatitis C Virus Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26TelapreVIH): An Open Label, Single-Arm, Phase 2 Trial. Clin Infect Dis. 59:1768-76. 2014
  95. Jennings CL, Sherman KE. Hepatitis C and HIV Co-Infection: New Drugs in Practice and in the Pipeline. Curr HIV/AIDS Rep. 9:231-7. 2012
  96. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol. 55:192-206. 2011
  97. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Special Report JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1. Hepatol Res. 44 (Suppl. 1): 59-70. 2014
  98. Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: A phase 3 study. Clin Infect Dis. 59:1579-87.2014
  99. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 21:762-8. 2014
  100. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 368:1878-87. 2013
  101. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 368:1867-77. 2013
  102. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 370:1993-2001. 2014
  103. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 312:353-61. 2014
  104. Molina J-M, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON- 2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 385:1098-106. 2015
  105. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 15: 645-53.2015
  106. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 370: 1889-98. 2014
  107. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-88. 2014
  108. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 370: 1483-93. 2014
  109. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 313: 1232-9.2015
  110. Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 373: 705-13. 2015
  111. Nagao A, Hanabusa H. The impact of ledipasvir/sofosbuvir on HIV-positive and HIV-negative Japanese hemophilia patients with 1, 4, and mixed-genotype HCV. J Acquir Immune Defic Syndr. 74:418-22. 2016
  112. Uemura H, Tsukada K, Mizushima D, et al. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders. Plos one. 12 (10) e0186255. 2017
  113. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 385:1087-97. 2015
  114. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO -INFECTION): a non- randomised, open- label trial. Lancet HIV. 2: e319-27. 2015
  115. Braun DL, Hampel B, Kouyos R, et al. High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men. Clin Infect Dis. 2018 Aug 13. doi: 10.1093/cid/ciy547. [Epub ahead of print].)
  116. Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology. 59: 2403-12. 2014
  117. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 33: 106-15. 2000
  118. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a metaanalysis of individual patient data. Gastroenterology.130:1636-1642.2006
  119. Bochud P-Y, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 51: 655-6. 2009
  120. Probst A, Dang T, Bochud M, et al. Role of Hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and metaanalysis. J Viral Hepatitis. 18: 745-59. 2011
  121. Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepatitis. 18: e516-e522. 2011
  122. Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308: 2584-93.2012
  123. Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepa
  124. Di Martino V, Richou C, Cervoni JP, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology. 54: 789-800. 2011
  125. Gane EJ, Hyland RH, An D, et al. Efficacy of Ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology.149:1454-61. 2015
  126. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: Ally-3 phase III study. Hepatology. 61:1127-35.2015
  127. Wyles DL, Ruane P, Sulkowski MS, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 373:714-25. 2015
  128. Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 17: 1062-8. 2017
  129. Wyles D, Poordad F, Wang S, et al. Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial. Hepatology. 67: 514-23. 2018
  130. Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 67 :1010-7. 2018
  131. Montes ML, Olveira A, Ahumada A, et al. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. AIDS. 31:1253–60. 2014
  132. Shafran SD. HIV coinfected have similar SVR rates as HCV mono-infected with DAAs: it's time to end segregation and integrate HIV patients into HCV trials. Clinical infectious diseases. 61: 1127-34. 2015
  133. Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med. 166:792-8. 2017
  134. Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 15:132-6. 2017
  135. Schwabl P, Mandorfer M, Steiner S, et al. Interferon free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther. 45: 139-49. 2017
  136. Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol. 30: 653-9. 1999
  137. Tanaka H, Tsukuma H, Kasahara A, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer. 87: 741-9. 2000
  138. Takimoto M, Ohkoshi S, Ichida T, et al. Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients. Dig Dis Sci. 47: 170-6. 2002
  139. Enokimura N, Shiraki K, Kawakita T, et al. Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C. Anticancer Res. 23: 593-6.2003
  140. Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 67:1204-12. 2017
  141. Merchante N, Rivero-Juarez A, Telletz F, et al. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. J Antimicrob Chemother. 73 :2435-43. 2018
  142. Salmon-Ceron D, Nahon P, Layese R, et al. HIV/HCV co-infected cirrhotic patients are no longer at higher risk for HCC or endstage liver disease as compared to HCV mono-infected patients. Hepatology. 2018 Dec 19. doi: 10.1002/hep.30400. [Epub ahead of print])
  143. 日本肝臓学会.C型肝炎治療ガイドライン(第6版http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c)p4
  144. Hasson H, Merli M, Messina E, Bhoori S, Salpietro S, Morsica G, Regalia E, Bagaglio S, Lazzarin A, Uberti-Foppa C, Mazzaferro V. Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. J Hepatol. 67: 415-7. 2017
  145. Carrieri MP, Protopopescu C, Marcellin F, et al. Protective effect of coffee consumption on all-cause mortality of French HIVHCV co-infected patients. J Hepatol. 67:1157-67. 2017

PAGE TOP

アンケートにご協力ください。

このページは役に立ちましたか?

コメント